8 April 2015 - Deborah Wilkes
Archived
Generics firm Mylan has offered to buy Perrigo in a cash and shares deal worth US$30.1 billion. The move comes just days after Perrigo completed the acquisition of Belgian OTC specialist Omega Pharma for €3.8 billion (US$4.2 billion) including the assumption of €1.3 billion in debt.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.